Yonsei Med J.  2010 May;51(3):448-450. 10.3349/ymj.2010.51.3.448.

Nonspecific Interstitial Pneumonitis after Bortezomib and Thalidomide Treatment in a Multiple Myeloma Patient

• Kang W
• Kim JS
• Cho SH
• Kim SK
• Chang J
• Park MS

• KMID: 1074999
• DOI: http://doi.org/10.3349/ymj.2010.51.3.448

Abstract

Bortezomib, an inhibitor of 26S proteosome, is recently approved treatment option for multiple myeloma. Thalidomide, a drug with immunomodulating and antiangiogenic effects, has also shown promise as an effective treatment in multiple myeloma. Pulmonary complications are believed to be rare, especially interstitial lung disease. Here, we describe a patient with dyspnea and diffuse pulmonary infiltrates while receiving bortezomib and thalidomide in combination with dexamethasone for treatment-naive multiple myeloma. Bronchoalveolar lavage demonstrated a significant decrease in the ratio of CD4 : CD8 T lymphocytes (CD4/8 ratio, 0.54). Extensive workup for other causes, including infections, was negative. A lung biopsy under video-assisted thorascopic surgery revealed a diagnosis of nonspecific interstitial pneumonitis. The symptoms and imaging study findings improved after initiating steroid treatment. Physicians should be aware of this potential complication in patients receiving the novel molecular-targeted antineoplastic agents, bortezomib and thalidomide, who present with dyspnea and new pulmonary infiltrates and fail to improve despite treatment with broad-spectrum antibiotics.

Keyword

Interstitial lung diseases; thalidomide; bortezomib; multiple myeloma; adverse effects

MeSH Terms

Aged
Boronic Acids/*adverse effects/therapeutic use
Dexamethasone/therapeutic use
Humans
Lung Diseases, Interstitial/*chemically induced
Male
Multiple Myeloma/*drug therapy
Pyrazines/*adverse effects/therapeutic use
Thalidomide/*adverse effects/therapeutic use

Figure

• 

  Fig. 1 Chest CT scans. (A and B) After the first cycle of triple regimen, at the time of clinical deterioration demonstrating newly developed subpleural reticulation and diffuse interstitial changes in both upper and mid-lungs with a ground glass appearance. (C and D) Six weeks after initiating the steroid treatment with marked improvement of interstitial pneumonitis.

• 

  Fig. 2 Video-assisted thoracoscopic lung biopsy photomicrographs (Hematoxylin Eosin staining). (A) Alveolar walls are thickened with diffuse interstitial fibrosis (original magnification ×12). (B) Interstitial fibrosis with characteristic temporal monogeneity is present with associated chronic interstitial inflammation, whereas fibroblastic foci are not seen (original magnification ×100).

Reference

1. Ghobrial IM, Leleu X, Hatjiharissi E, Hideshima T, Mitsiades C, Schlossman R, et al. Emerging drugs in multiple myeloma. Expert Opin Emerg Drugs. 2007. 12:155–163.

2. Richardson PG, Hideshima T, Mitsiades C, Anderson KC. The emerging role of novel therapies for the treatment of relapsed myeloma. J Natl Compr Canc Netw. 2007. 5:149–162.

3. Colson K, Doss DS, Swift R, Tariman J, Thomas TE. Bortezomib, a newly approved proteasome inhibitor for the treatment of multiple myeloma: nursing implications. Clin J Oncol Nurs. 2004. 8:473–480.

4. Dimopoulou I, Bamias A, Lyberopoulos P, Dimopoulos MA. Pulmonary toxicity from novel antineoplastic agents. Ann Oncol. 2006. 17:372–379.

5. Onozawa M, Hashino S, Sogabe S, Haneda M, Horimoto H, Izumiyama K, et al. Side effects and good effects from new chemotherapeutic agents. Case 2. Thalidomide-induced interstitial pneumonitis. J Clin Oncol. 2005. 23:2425–2426.

6. Jagannath S, Barlogie B, Berenson JR, Singhal S, Alexanian R, Srkalovic G, et al. Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impaired renal function. Cancer. 2005. 103:1195–1200.

7. Miyakoshi S, Kami M, Yuji K, Matsumura T, Takatoku M, Sasaki M, et al. Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma. Blood. 2006. 107:3492–3494.